BioRestorative issued 3 patents for stem cell platform

By The Science Advisory Board staff writers

March 22, 2021 -- BioRestorative Therapies has been issued three separate patents related to the company's metabolic ThermoStem stem cell program.

The patents relate to a specific isolated stem cell derived from human brown adipose tissue that's capable of differentiating into multiple cell types. These cells have potential therapeutic uses for treating a wide range of degenerative and metabolic disorders.

The ThermoStem platform technology can be used to develop cell-based therapy candidates that mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.

The notices of allowances cover the U.S., Israel, France, Germany, Italy, Spain, and the U.K. The applications have been issued or are expected to issue as patents in 2021.

Control of molecular 'doormen' in fat cells offers potential new obesity treatment
New treatment options for obesity could emerge from a study published in Nature Communications on January 10. Researchers from Yale University...
Researchers use drug repurposing to identify new treatment for Metabolic Syndrome
A research team from the University of Trento find a novel method for using old drugs in new ways, specifically for Metabolic Syndrome. This revolutionary...

Copyright © 2021

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter